Zymeworks Inc.

ZYME · Nasdaq · SIC 2834: Pharmaceutical Preparations
100
SEC Filings

Business Summary

PART I Overview Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty...

Next Earnings

Q2 FY2026 — expected 2026-09-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionZYMEdiscussed_in_filing Cybersecurity
topic_mentionZYMEdiscussed_in_filing Trusted Computing
topic_mentionZYMEdiscussed_in_filing Blockchain & Crypto
topic_mentionZYMEdiscussed_in_filing Capital Expenditure
topic_mentionZYMEdiscussed_in_filing Regulation
topic_mentionZYMEdiscussed_in_filing Healthcare & Bio
topic_mentionZYMEdiscussed_in_filing Platform & Ecosystem
topic_mentionZYMEdiscussed_in_filing Sovereign & Government
topic_mentionZYMEdiscussed_in_filing Cybersecurity
topic_mentionZYMEdiscussed_in_filing Trusted Computing
topic_mentionZYMEdiscussed_in_filing Blockchain & Crypto
topic_mentionZYMEdiscussed_in_filing Capital Expenditure
topic_mentionZYMEdiscussed_in_filing Regulation
topic_mentionZYMEdiscussed_in_filing Healthcare & Bio
topic_mentionZYMEdiscussed_in_filing Platform & Ecosystem
topic_mentionZYMEdiscussed_in_filing Sovereign & Government
topic_mentionZYMEdiscussed_in_filing Cybersecurity
topic_mentionZYMEdiscussed_in_filing Trusted Computing
topic_mentionZYMEdiscussed_in_filing Blockchain & Crypto
topic_mentionZYMEdiscussed_in_filing Capital Expenditure

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-022025-12-310001937653-26-000015EDGAR115K words
2025-03-052024-12-310001937653-25-000014EDGAR
2024-03-062023-12-310001937653-24-000019EDGAR
2023-03-072022-12-310001937653-23-000011EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001937653-25-000077EDGAR65K words
2025-08-072025-06-300001937653-25-000049EDGAR
2025-05-082025-03-310001937653-25-000027EDGAR
2024-10-312024-09-300001937653-24-000050EDGAR
2024-08-012024-06-300001937653-24-000041EDGAR
2024-05-022024-03-310001937653-24-000028EDGAR
2023-11-072023-09-300001937653-23-000037EDGAR
2023-08-102023-06-300001937653-23-000028EDGAR
2023-05-082023-03-310001937653-23-000018EDGAR
2022-11-082022-09-300001937653-22-000009EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-010001193125-26-135610EDGAR12K words
2026-03-020001193125-26-084082EDGAR
2026-03-020001937653-26-000013EDGAR
2026-01-120001193125-26-010480EDGAR
2025-12-300001193125-25-337268EDGAR
2025-11-180001193125-25-285259EDGAR
2025-11-170001193125-25-283873EDGAR
2025-11-060001937653-25-000076EDGAR
2025-09-020001193125-25-193351EDGAR
2025-08-110001193125-25-177505EDGAR

100 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001937653
TickerZYME
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: bf6654b8f04433b4cf52242f343a71e079b6e224220d19f111bfd0caf50eaa1b
parent: 9f01c46cfb30efb25ee5e672b75d675ca08ec3321d429c8dca6812e317b61698
content hash: 2a3467e176bcfc4be9125a04260937e72a02df00e3c7e7a5e1ed60916c013dd5
signed: 2026-04-13T04:48:24.278Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf